Check the time stamp on this data. Updated AI-Generated Signals for Crispr Therapeutics Ag (CRSP) available here: CRSP. Type ...
Leerink Partners analyst Mani Foroohar has maintained their bullish stance on CRSP stock, giving a Buy rating on January 13.Stay Ahead of the ...
Zacks.com on MSN11h
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You TradeCRISPR Therapeutics AG (CRSP) closed the most recent trading day at $38.36, moving -1.26% from the previous trading session.
Crispr Therapeutics AG (CRSP) stock saw a decline, ending the day at $38.85 which represents a decrease of $-0.84 or -2.12% from the prior close of $39.69. The stock opened at $39.06 and touched a low ...
OptionMetrics and CRSP provide increased integration of U.S. equities and options data for use in academic research ...
Brookstone Capital Management raised its holdings in Vanguard Mega Cap Growth ETF (NYSEARCA:MGK – Free Report) by 12.1% ...
VUG ETF invests in large-cap growth stocks. Check out 3 key reasons why the fund might not be a good choice from a portfolio ...
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target lowered by Bank of America from $98.00 to $85.00 in ...
As of 3:05:34 pm GMT-5. Market open. ZUG, Switzerland and BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative ...
NEW YORK & CHICAGO–(BUSINESS WIRE)–OptionMetrics, an options database and analytics provider for institutional investors and academic researchers worldwide, and CRSP, Center for Research in Security ...
Analyst Gil Blum from Needham maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) and keeping the price target at ...
The Vanguard US Total Market Shares Index ETF (ASX: VTS) outperformed the Vanguard Australian Shares Index ETF (ASX: VAS) by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback